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Summary 
 
A recent study claimed that genome-wide polygenic scores (GPSs) for five common diseases could 
identify individuals with risk equivalent to monogenic mutations. Receiver operator curve analyses 
were reported to have areas under the curve (AUCs) ranging from 0.63 for inflammatory bowel 
disease up to 0.81 for coronary artery disease (CAD) but these models also included age and sex, 
themselves strong predictors of risk. The GPS for CAD identified 8% of the population at threefold 
increased risk, which it was claimed was comparable to the excess risk from monogenic mutations. 
 
In the present study attempts were made to model the distribution of the GPS for CAD to match the 
information provided. These models were based on the reported distribution of prevalence by 
centile of GPS and on the distribution of GPS in controls and cases and were fitted to the reported 
results using linear approximations to the distributions and using simulations of a liability-threshold 
model. 
 
It was impossible to produce a compatible model in which the GPS produced an AUC as high as 0.81 
and the most plausible estimate was that the true AUC was only 0.65. The reported distributions of 
the GPS in cases and controls overlap so much that they are not compatible with an AUC of 0.7 or 
higher. 
 
The AUC of the GPS for these diseases is modest. Furthermore, the literature robustly demonstrates 
that true CAD risk associated with monogenic mutations is much higher than the threefold increase 
which is predicted by the GPS. Together, these findings cast doubt on the clinical utility of the GPS. 
 
 
Introduction 
 
A recent study has claimed that genome-wide polygenic scores (GPS) for five common diseases could 
identify individuals with risk equivalent to monogenic mutations (Khera et al. 2018). Using GPS to 
predict risk it was reported that the area under the receiver operating curve (AUC) was high for all 
five diseases tested, ranging from 0.63 for inflammatory bowel disease up to 0.81 for coronary 
artery disease (CAD) but these models additionally included age and sex and population principal 
components as predictors. No information was given regarding the AUC for GPS alone or the extent 
to which the AUC increased when GPS was added to the other predictors. Figures were presented 
which provided some information about the distribution of GPS for CAD in controls and cases and 
the prevalence of CAD across different centiles of the GPS. It was reported that for CAD the GPS 
could identify 8% of the population at greater than threefold increased risk, and this was contrasted 
with the 0.4% carrying a familial hypercholesterolemia (FH) mutation which, it was claimed, “confers 
an up to threefold increased risk for CAD”. 
Here I model the system based on the information presented in these figures and the accompanying 
text and show that the AUCs for GPS alone are substantially lower than those presented. I also point 
out that the FH mutation has a much larger than threefold effect on risk, directly challenging the 
claim that the GPS identifies “individuals with risk equivalent to monogenic mutations”. 
 
Methods 
The relationship between GPS and CAD risk was modelled in three different ways. 
The first approach used a simple approximation to the graph of CAD prevalence (%) against GPS 
centile which had been presented in Figure 2c of the original report. The prevalence (%) was 
reported to be 0.8 for the lowest centile and 11.1 for the highest but the curve is markedly concave 
so two linear segments were used (with x=centile, y=prevalence), from (1, 0.8) to (90, 4) and then 
from (90, 4) to (100, 11.1). From these interpolated prevalences, the sensitivity and specificity were 
calculated for each GPS centile and these values were used to calculate the AUC. 
The second approach used the GPS medians and intra-quartile ranges to model the sensitivity and 
specificity. The medians for controls and cases were reported as 49 and 69 respectively, and from 
Figure 2b of the original report it appears that the intra-quartile ranges are approximately 23-73 and 
44-89. This meant that the distribution of specificity for controls could be modelled (with x=centile, 
y=specificity) by having four linear segments passing through the points (0, 0; 23, 0.25; 49, 0.5; 73, 
0.75; 100, 1) and sensitivity for cases with four linear segments passing through the points (0, 1; 44, 
0.75; 69, 0.5; 89, 0.25; 100, 0). Again, the AUC was then calculated from these values. 
The third approach was to simulate a liability threshold model with the liability as the sum of a 
normally distributed component tagged by the GPS and a normally distributed residual component. 
These two components were assumed to contribute additively to the liability and all subjects with a 
resultant liability exceeding a threshold were designated cases. 100,000 subjects were used in the 
simulation. The model is parameterised by the proportion of liability variance accounted for by the 
GPS, denoted P, and the population prevalence K. An iterative approach was used to select values of 
P and K which would produce a graph of prevalence against GPS centile which approximated the 
original Figure 2c. The distribution of GPS in cases and controls was then examined, along with the 
specificity, sensitivity and AUC.  
An excel spreadsheet and R code to produce the models used are provided at 
https://github.com/davenomiddlenamecurtis/modelGPS. 
 Results 
The first approach, of approximating the prevalence distribution, yielded a value for the AUC of 0.65. 
The second approach, using linear interpolations of the sensitivity and specificity, produced an AUC 
of 0.64. In this scenario the sensitivity and specificity were equal in the 59th centile, both having a 
value of 0.60. This implies that the graph of sensitivity against specificity would pass through the 
point (0.60, 0.60), implying that even a maximally convex curve could not have AUC greater than 
about 0.65. For the third approach, values for P and K of 0.06 and 0.04 produced distributions which 
seemed to match fairly well with those originally reported. The graph of prevalence against centile 
of PGS is shown in Figure 1 and this approximates to the distribution shown in Figure 2c of the 
original publication. The values chosen produce control and case medians of 51 and 71 with IQRs of 
26-76 and 46-90, acceptably close to the originals. The AUC for this model is 0.65. In general, the 
value for the AUC is not very sensitive to the parameter values chosen. It was possible to increase 
the AUC to 0.80 only by increasing P to 0.17 and reducing K to 0.01. However with these values the 
medians were 51 and 88 and IQRs were 26-76 and 71-98, completely discrepant from those reported 
for the real data. No model could be found with an AUC of 0.7 or more which yielded values even 
approximately resembling those displayed in the original Figures 2b and 2c. There is a large overlap 
in IQRs between controls and cases and the medians of the centiles are only separated by 20 and 
these features imply that no compatible model can produce an AUC as high as 0.7.  
 
Discussion 
The original claim that the AUC for risk of CAD is 0.81 is dependent on including age and sex as 
predictors whereas the AUC for GPS alone would be substantially lower. The IQRs for controls and 
cases largely overlap and the medians are not far enough apart to produce a high AUC and the best 
estimate for the true value is around 0.65. This discrepancy is important because the AUC is widely 
used as a rule of thumb as to whether a screening test is likely to be clinically relevant. The other 
diseases studied were reported to have similar risk profiles with smaller claimed AUCs than for CAD 
so it seems reasonable to assume that the AUCs for GPS alone would also be low. In general, a test 
with an AUC of 0.65 or less would not be expected to be used in clinical practice. 
Another problem with the original report is the claim that the FH mutation “confers an up to 
threefold increased risk”. The source cited to produce a this estimate of risk for monogenic 
mutations (OR around 3) was based on a sample of exome-sequenced subjects in a health insurance 
scheme with a median age of 61 (Abul-Husn et al. 2016). Such a sample would be expected to be 
significantly depleted for relevant mutations because subjects with them who had become unwell 
might have have been removed from the scheme, leading to an under-estimate of their effect size. 
However, according to the consensus statement of the European Atherosclerosis Society the real 
effect size is much higher, “up to 13-fold increased risk”, and “men and women with heterozygous 
FH typically develop CHD before age 55 and 60, respectively, while homozygotes typically develop 
CHD very early in life and if untreated die before age 20” (Nordestgaard et al. 2013). However, for 
subjects in the very highest centile of GPS for CAD, the prevalence of CAD was stated to be only 
11.1%. Thus, the claim that the risk identified by GPS is "comparable" with the risk from monogenic 
mutations does not seem to be justified.  
Given that the performance of the GPS as a predictor is modest and that the magnitude of effects of 
monogenic mutations has been understated, the claim that “genome-wide polygenic scores for 
common diseases identify individuals with risk equivalent to monogenic mutations” cannot be 
justified. 
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Figure 1 Graph of prevalence against PGS centile using a liability threshold model with P=0.06, 
K=0.04. The distribution is similar to that shown in Figure 2c of the original report. 
 
